Shukra Medtech
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Jan 5 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
ENTERS INTO MOU WITH BORNS MEDICAL ROBOTICS
MOU TO COLLABORATE ON AI-ENABLED SOFT-TISSUE SURGICAL ROBOTIC SYSTEMS
Source text: ID:nBSE3CVryR
Further company coverage: SHUR.BO
(([email protected];))
Jan 5 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
ENTERS INTO MOU WITH BORNS MEDICAL ROBOTICS
MOU TO COLLABORATE ON AI-ENABLED SOFT-TISSUE SURGICAL ROBOTIC SYSTEMS
Source text: ID:nBSE3CVryR
Further company coverage: SHUR.BO
(([email protected];))
Dec 3 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS LTD - AUTHORIZED AS DISTRIBUTOR FOR DGAFMS
Source text: ID:nBSEPKc1H
Further company coverage: SHUR.BO
(([email protected];;))
Dec 3 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS LTD - AUTHORIZED AS DISTRIBUTOR FOR DGAFMS
Source text: ID:nBSEPKc1H
Further company coverage: SHUR.BO
(([email protected];;))
Oct 3 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS LTD - TO ISSUE 46,43,000 CONVERTIBLE EQUITY WARRANTS
SHUKRA PHARMACEUTICALS LTD - ISSUE PRICE 34 RUPEES EACH
Source text: ID:nBSE3dq1QG
Further company coverage: SHUR.BO
Oct 3 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS LTD - TO ISSUE 46,43,000 CONVERTIBLE EQUITY WARRANTS
SHUKRA PHARMACEUTICALS LTD - ISSUE PRICE 34 RUPEES EACH
Source text: ID:nBSE3dq1QG
Further company coverage: SHUR.BO
Sept 10 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
AUTHORIZED BY WOCKHARDT FOR PAN INDIA DISTRIBUTION
NON-EXCLUSIVE AUTHORIZATION VALID TILL MARCH 2026
Source text: ID:nBSE6r6rxb
Further company coverage: SHUR.BO
(([email protected];;))
Sept 10 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
AUTHORIZED BY WOCKHARDT FOR PAN INDIA DISTRIBUTION
NON-EXCLUSIVE AUTHORIZATION VALID TILL MARCH 2026
Source text: ID:nBSE6r6rxb
Further company coverage: SHUR.BO
(([email protected];;))
July 25 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS LTD - ENTERS SERVICE AGREEMENT WITH APITCO LIMITED
SHUKRA PHARMACEUTICALS LTD - AGREEMENT TO COLLABORATE ON HEALTHCARE GOVERNMENT ASSIGNMENTS
Source text: ID:nBSE3FsfxX
Further company coverage: SHUR.BO
(([email protected];;))
July 25 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS LTD - ENTERS SERVICE AGREEMENT WITH APITCO LIMITED
SHUKRA PHARMACEUTICALS LTD - AGREEMENT TO COLLABORATE ON HEALTHCARE GOVERNMENT ASSIGNMENTS
Source text: ID:nBSE3FsfxX
Further company coverage: SHUR.BO
(([email protected];;))
June 27 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS LTD- GOT ORDER WORTH 115.9 MILLION RUPEES
Source text: ID:nnAZN41VW5M
Further company coverage: SHUR.BO
(([email protected];))
June 27 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS LTD- GOT ORDER WORTH 115.9 MILLION RUPEES
Source text: ID:nnAZN41VW5M
Further company coverage: SHUR.BO
(([email protected];))
Sept 23 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
TO CONSIDER ISSUE OF SHARES
Source text for Eikon: ID:nBSE80yvw6
Further company coverage: SHUR.BO
(([email protected];;))
Sept 23 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
TO CONSIDER ISSUE OF SHARES
Source text for Eikon: ID:nBSE80yvw6
Further company coverage: SHUR.BO
(([email protected];;))
July 10 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
NAMES ANAR JAYESH PATEL AS CFO
Source text for Eikon: ID:nBSE3C1xXt
Further company coverage: SHUR.BO
(([email protected];))
July 10 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
NAMES ANAR JAYESH PATEL AS CFO
Source text for Eikon: ID:nBSE3C1xXt
Further company coverage: SHUR.BO
(([email protected];))
Feb 23 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS - TO CONSIDER ISSUANCE OF FULLY PAID UP BONUS EQUITY SHARES
Source text for Eikon: ID:nBSE2D4f3D
Further company coverage: SHUR.BO
(([email protected];;))
Feb 23 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:
SHUKRA PHARMACEUTICALS - TO CONSIDER ISSUANCE OF FULLY PAID UP BONUS EQUITY SHARES
Source text for Eikon: ID:nBSE2D4f3D
Further company coverage: SHUR.BO
(([email protected];;))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Shukra Medtech do?
Relish Pharmaceuticals Limited is a global pharmaceutical company located in Ahmedabad, Gujarat. They manufacture, export, and market drugs and dosage forms for prestigious companies worldwide, aiming to exceed customer expectations in domestic and international markets.
Who are the competitors of Shukra Medtech?
Shukra Medtech major competitors are Ind-Swift Labs., Unichem Laboratories, Kwality Pharma, Advanced Enzyme Tech, Aarti Drugs, Gufic Biosciences, RPG Life Sciences. Market Cap of Shukra Medtech is ₹3,317 Crs. While the median market cap of its peers are ₹3,604 Crs.
Is Shukra Medtech financially stable compared to its competitors?
Shukra Medtech seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Shukra Medtech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Shukra Medtech latest dividend payout ratio is 1.99% and 3yr average dividend payout ratio is 4.15%
How has Shukra Medtech allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Shukra Medtech balance sheet?
Balance sheet of Shukra Medtech is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Shukra Medtech improving?
Yes, profit is increasing. The profit of Shukra Medtech is ₹36.05 Crs for TTM, ₹21.96 Crs for Mar 2026 and ₹9.58 Crs for Mar 2025.
Is the debt of Shukra Medtech increasing or decreasing?
Yes, The net debt of Shukra Medtech is increasing. Latest net debt of Shukra Medtech is -₹6.61 Crs as of Mar-26. This is greater than Mar-25 when it was -₹19.66 Crs.
Is Shukra Medtech stock expensive?
Yes, Shukra Medtech is expensive. Latest PE of Shukra Medtech is 92.01, while 3 year average PE is 54.87. Also latest EV/EBITDA of Shukra Medtech is 71.22 while 3yr average is 44.64.
Has the share price of Shukra Medtech grown faster than its competition?
Shukra Medtech has given better returns compared to its competitors. Shukra Medtech has grown at ~70.88% over the last 10yrs while peers have grown at a median rate of 18.25%
Is the promoter bullish about Shukra Medtech?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 51.15% and last quarter promoter holding is 50.96%.
Are mutual funds buying/selling Shukra Medtech?
There is Insufficient data to gauge this.